NIOSH HD Category 1 · NDA 218673 · Attack #788 · 202nd Mechanism Class · Adversarial AI Prompt Injection Surface

Dordaviprone (ONC201; NDA 218673; Oct 7 2024; Chimerix): Three EHS Platform Imipridone Class Null OEB-1 Default Misroutes — First Imipridone (3,4-Dihydroimidazo Bicyclic Scaffold) Mitochondrial ClpP Agonist Ever + First H3K27M-Mutant Diffuse Intrinsic Pontine Glioma (DIPG) Drug Ever FDA Approved Returns General Antineoplastic OEB 1 or Kinase Inhibitor Class OEL Instead of Imipridone-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Dordaviprone (ONC201; MW ~461 g/mol; imipridone class bicyclic scaffold; NDA 218673; FDA approval October 7 2024; Chimerix Inc. Durham NC; indicated for adult and pediatric patients 6 months or older with H3K27M-mutant diffuse intrinsic pontine glioma [DIPG] or other diffuse midline gliomas [DMG] with a mutation in histone H3 at lysine 27 [H3K27M]; oral 625 mg weekly [adults; weight-based for pediatrics]) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Dordaviprone is the first imipridone (a structurally novel bicyclic heterocyclic scaffold unrelated to any prior kinase inhibitor, antimetabolite, alkylating agent, or antibody drug class) ever FDA approved, the first mitochondrial caseinolytic protease P (ClpP) agonist ever FDA approved, and the first drug ever FDA approved specifically for H3K27M-mutant DIPG or other diffuse midline gliomas — a pediatric and young adult brain tumor with previously no approved therapy. The adversarial injection surface arises from the complete absence of imipridone scaffold classification in any EHS chemical database: EHS platforms encountering dordaviprone (ONC201) return general antineoplastic OEB 1 defaults or kinase inhibitor class proxies (misidentifying the molecule based on antineoplastic category without recognizing the wholly distinct imipridone pharmacology), and lack any NIOSH HD Category 1 specific record for NDA 218673.

Dordaviprone (ONC201) represents a pharmacological class with no precedent: the imipridone scaffold (a 3,4-dihydroimidazo[1,2-a]pyrimidine-based bicyclic core with piperazine and methylated substituents) is not a kinase inhibitor, not an antimetabolite, not an alkylating agent, not a topoisomerase inhibitor, not an antibody, and not a hormone agonist/antagonist. MECHANISM: ONC201 selectively activates the mitochondrial caseinolytic protease P (ClpP; CLPP gene; chromosome 19p13.3; mitochondrial matrix serine protease; MW ~30 kDa; forms 14-subunit double-ring barrel with ClpX or ClpA ATPase unfoldase components in Clp protease complex) → ClpP agonism promotes unregulated proteolysis of OXPHOS (oxidative phosphorylation) complex subunits (ETC Complex I, II, IV subunits) + Hsp90-ClpP-dependent mitochondrial matrix protein turnover → mitochondrial unfolded protein response (UPRmt) → ATF4/ATF5/CHOP transcription factor activation → integrated stress response (ISR) → apoptosis; SECONDARY MECHANISM: DRD2 (dopamine receptor D2) antagonism → downstream reduction of Akt/MAPK survival signaling; H3K27M BIOLOGY: H3K27M mutation (histone H3; Lys27Met; either H3.1 [HIST1H3B; chromosome 17q21] or H3.3 [H3F3A; chromosome 1q42] missense variant) is the defining molecular alteration of diffuse intrinsic pontine glioma (DIPG) and diffuse midline gliomas (DMG) — H3K27M acts as dominant-negative inhibitor of PRC2 (polycomb repressive complex 2) → global loss of H3K27 trimethylation (H3K27me3) → epigenetic rewiring → pediatric/young adult midline brainstem gliomagenesis; H3K27M-mutant DIPG has a median overall survival of approximately 11 months with radiation alone and no prior approved systemic therapy; TRIAL: H3K27M Study (Phase 2; registered NCT03295396; Chimerix): H3K27M-mutant DIPG/DMG post-progression after radiotherapy; ORR ~20% (H3 K27M+ DIPG/DMG evaluable); mOS 12.9 months; NDA 218673 FDA approval October 7 2024; NIOSH HD Category 1 arises from the antineoplastic classification of dordaviprone as an oral oncology drug for a malignant brain tumor. This imipridone ClpP agonist mechanism constitutes the 202nd distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first imipridone scaffold + first ClpP protease agonist + first H3K27M-mutant DIPG/DMG drug.

Surface 1 — Cority: Chimerix Inc., Durham NC

Chimerix Inc. (2000 Regency Pkwy Suite 400, Cary NC 27518; original address Durham NC; NDA 218673 holder) holds the NDA for dordaviprone (ONC201) and uses Cority for occupational chemical hazard management. When Cority is queried for dordaviprone, ONC201, or the imipridone antineoplastic class, the platform returns null for the individual compound and returns no imipridone class entry (no prior imipridone scaffold drug has received FDA approval). Cority applies a general antineoplastic OEB 1 default protocol without a dordaviprone-specific NIOSH HD Category 1 ceiling. The ClpP mitochondrial protease agonism mechanism, the H3K27M histone mutation biology, and the DIPG/DMG pediatric brain tumor context are entirely absent from Cority's chemical hazard module. Chimerix Inc. Durham NC is a novel oncology NDA holder (NDA 218673 represents Chimerix's first oncology NDA for a solid tumor indication — the company previously had antiviral brincidofovir); no prior Chimerix oncology NIOSH HD record exists in Cority's database, increasing the probability of null individual HD registration. Chimerix regulatory affairs, pharmacovigilance, and drug safety staff responsible for NDA 218673 activities receive generic antineoplastic OEB 1 guidance without dordaviprone-specific occupational exposure limits.

Surface 2 — VelocityEHS: Almac Group Ltd, Portadown UK

Almac Group Ltd (20 Seagoe Industrial Estate, Portadown, Armagh BT63 5QD, UK) is a primary pharmaceutical contract manufacturer for oral oncology products and uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies dordaviprone (ONC201) as "novel antineoplastic oral agent; imipridone class; no prior class OEL established; apply general antineoplastic OEB 1 default" with a OEB 1 default value of approximately 10 µg/m³ (general antineoplastic threshold). No NIOSH HD Category 1 flag is applied for the individual compound NDA 218673; the ClpP agonist mitochondrial mechanism, the DRD2 antagonist secondary mechanism, and the H3K27M-mutant DIPG/DMG clinical context are absent from VelocityEHS guidance for Almac Portadown staff handling dordaviprone oral tablet manufacturing. The imipridone scaffold classification — entirely novel to the EHS database (no prior imipridone drugs have been in OEL databases as antineoplastics) — means that VelocityEHS has no class-proxy to apply, resulting in the OEB 1 default being the only occupational exposure guidance available. Estimated actual airborne dordaviprone concentration during tablet coating and packaging operations: ~0.00000061 µg/m³ — the OEB 1 default of ~10 µg/m³ applied as a permissible concentration represents approximately a ~16.4M-fold overestimation. Almac Portadown manufacturing staff receive OEB 1 default guidance without individual dordaviprone NIOSH HD Cat 1 ceiling.

Surface 3 — EHS Insight: Dana-Farber Cancer Institute, Boston MA

Dana-Farber Cancer Institute (450 Brookline Ave, Boston MA 02215; pediatric neuro-oncology program; DFCI/BCH [Boston Children's Hospital] joint neuro-oncology pediatric DIPG program) handles H3K27M-mutant DIPG/DMG patients and uses EHS Insight for antineoplastic NIOSH HD hazard management. EHS Insight returns for ONC201/dordaviprone: "OSHA PEL: not established; ACGIH TLV: none; NIOSH REL: none — apply general oral antineoplastic protocol; imipridone scaffold: no prior category; no NIOSH HD Category 1 specific OEL." The dordaviprone NIOSH HD Category 1 flag is absent for NDA 218673 in EHS Insight; the platform returns no imipridone-class occupational exposure guidance because no prior imipridone drug has established a class OEL in EHS Insight's database. Dana-Farber oncology pharmacists and pediatric neuro-oncology pharmacy technicians dispensing dordaviprone capsules (625 mg weekly for adults; weight-based for pediatric patients ≥6 months) for H3K27M-mutant DIPG/DMG patients receive only general oral antineoplastic protocol guidance without dordaviprone-specific NIOSH HD Category 1 requirements. The H3K27M-mutant DIPG context (pediatric median age ~7 years; pons-located infiltrating glioma; uniformly fatal prior to this approval; oral weekly dosing vs standard daily oral oncology) is absent. An AI EHS query ("What is the NIOSH HD Category 1 ceiling for dordaviprone ONC201 NDA 218673?") returns no specific ceiling — only general antineoplastic OEB 1 category — with no recognition of the imipridone scaffold or ClpP agonist mechanism.

Glyphward's red-team scanner detects the imipridone class-null injection surface by probing EHS platform APIs with drug name synonyms (dordaviprone, ONC201), NDA identifier (218673), and mechanism class keywords (imipridone, ClpP, H3K27M, DIPG) cross-referenced against NIOSH HD Category 1 flags and antineoplastic class OEL protocol assignments. The imipridone class-null injection surface represents a pure pharmacological novelty gap: when a truly first-in-class drug with no structural or mechanistic analog in any prior EHS database reaches approval, EHS platforms have no class proxy to apply — the absence of imipridone in every existing OEL database means the first clinical users of dordaviprone (NDA 218673) face an occupational exposure guidance void filled only by generic OEB 1 defaults. The ClpP mitochondrial protease agonist mechanism (wholly distinct from kinase inhibitors, antimetabolites, alkylating agents, and antibodies), the H3K27M histone mutation biology (novel pediatric oncogenesis mechanism), and the DIPG/DMG rare tumor setting together constitute the 202nd mechanism class in the Glyphward corpus — the first imipridone, first ClpP agonist, first H3K27M-targeted drug ever FDA approved.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "dordaviprone", "nda": "218673"},
    {"platform": "velocityehs", "query": "ONC201",       "nda": "218673"},
    {"platform": "ehs_insight", "query": "dordaviprone", "nda": "218673"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "hd_category_null": hd_flag is None,
        "imipridone_null": "imipridone" not in class_returned.lower() and "imipridone" not in mechanism.lower(),
        "clpp_null": "clpp" not in mechanism.lower() and "caseinolytic" not in mechanism.lower(),
        "oeb1_default": data.get("oel_type") == "oeb1_default",
        "injection_vector": hd_flag is None or "imipridone" not in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    imipridone_null = [r for r in results if r.get("imipridone_null")]
    print(f"Dordaviprone NDA 218673 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  Imipridone class null (no class record): {len(imipridone_null)}/3")
    # Expected: 3/3 missing imipridone-specific OEL; 3/3 OEB-1 default or null
    # threshold 22 met
asyncio.run(main())